Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:antidote |
opioids
|
| gptkbp:approvedBy |
gptkb:FDA
1971 |
| gptkbp:ATCCode |
V03AB15
|
| gptkbp:availableOn |
injectable solution
nasal spray |
| gptkbp:brand |
gptkb:naloxone
|
| gptkbp:chemicalFormula |
C19H21NO3
|
| gptkbp:cost |
varies by country and formulation
|
| gptkbp:genericAvailable |
yes
|
| gptkbp:halfLife |
30-81 minutes
|
| https://www.w3.org/2000/01/rdf-schema#label |
Narcan
|
| gptkbp:includedIn |
gptkb:WHO_Model_List_of_Essential_Medicines
|
| gptkbp:legalStatus |
over-the-counter (US, as of 2023)
prescription-only (US) |
| gptkbp:manufacturer |
gptkb:Emergent_BioSolutions
|
| gptkbp:notEffectiveAgainst |
non-opioid overdoses
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:reversalOf |
respiratory depression
|
| gptkbp:routeOfAdministration |
intramuscular
intravenous intranasal |
| gptkbp:sideEffect |
nausea
vomiting hypertension sweating tachycardia agitation |
| gptkbp:storage |
room temperature
|
| gptkbp:usedFor |
opioid overdose
|
| gptkbp:bfsParent |
gptkb:Emergent_BioSolutions
|
| gptkbp:bfsLayer |
5
|